(Q38018632)

27 August 2017

title

Sulfonamides: a patent review (2008 - 2012). (English)

1 reference

27 August 2017

2

1 reference

27 August 2017

Fabrizio Carta

1

0 references

Claudiu T Supuran

series ordinal

3

object named as

Claudiu T Supuran

1 reference

27 August 2017

language of work or name

English

0 references

publication date

15 June 2012

1 reference

Expert Opinion on Therapeutic Patents

27 August 2017

published in

1 reference

27 August 2017

volume

22

1 reference

27 August 2017

issue

7

1 reference

27 August 2017

page(s)

747-758

1 reference

Carbonic anhydrases: novel therapeutic applications for inhibitors and activators

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrases as drug targets--an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Anticancer and antiviral sulfonamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors: sulfonamides as antitumor agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Indisulam: an anticancer sulfonamide in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Novel therapies for glaucoma: a patent review 2007 - 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Efficacy of Low-dose Acetazolamide (125 mg BID) for the Prophylaxis of Acute Mountain Sickness: A Prospective, Double-blind, Randomized, Placebo-controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors. Interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: kinetic and X-ray crystallographic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Adverse cardiovascular effects of the coxibs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors. Sulfonamide diuretics revisited--old leads for new applications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

The pharmacology of antiglaucoma drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic Anhydrase Inhibition/Activation: Trip of a Scientist Around the World in the Search of Novel Chemotypes and Drug Targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Inhibition and binding studies of carbonic anhydrase isozymes I, II and IX with benzimidazo[1,2-c][1,2,3]thiadiazole-7-sulphonamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Interfering with pH regulation in tumours as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Recent developments in targeting carbonic anhydrase IX for cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Sulfonamides incorporating 1,3,5-triazine moieties selectively and potently inhibit carbonic anhydrase transmembrane isoforms IX, XII and XIV over cytosolic isoforms I and II: Solution and X-ray crystallographic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors: synthesis of sulfonamides incorporating dtpa tails and of their zinc complexes with powerful topical antiglaucoma properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors: synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Protein tyrosine kinase inhibitors: new treatment modalities?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Pazopanib: Clinical development of a potent anti-angiogenic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

The therapy of kidney cancer with biomolecular drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Pazopanib: a promising new agent in the treatment of soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Pazopanib for the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Sulfonamide derivatives with protease inhibitory action as anticancer, anti-inflammatory and antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Antiglaucoma Carbonic Anhydrase Inhibitors as Ophthalomologic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic Anhydrase Inhibitors: X-ray and Molecular Modeling Study for the Interaction of a Fluorescent Antitumor Sulfonamide with Isozyme II and IX

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic Anhydrase Inhibitors. Synthesis of Water-Soluble, Topically Effective, Intraocular Pressure-Lowering Aromatic/Heterocyclic Sulfonamides Containing Cationic or Anionic Moieties: Is the Tail More Important than the Ring?1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic Anhydrase Inhibitors: Perfluoroalkyl/Aryl-Substituted Derivatives of Aromatic/Heterocyclic Sulfonamides as Topical Intraocular Pressure-Lowering Agents with Prolonged Duration of Action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Carbonic anhydrase inhibitors — Part 53. Synthesis of substituted-pyridinium derivatives of aromatic sulfonamides: The first non-polymeric membrane-impermeable inhibitors with selectivity for isozyme IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

Protein tyrosine kinase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.698264

10.1517/13543776.2012.698264

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference